245 related articles for article (PubMed ID: 33668625)
1. Cross-Reactivity and Functionality of Approved Human Immune Checkpoint Blockers in Dogs.
Pantelyushin S; Ranninger E; Guerrera D; Hutter G; Maake C; Markkanen E; Bettschart-Wolfensberger R; Rohrer Bley C; Läubli H; Vom Berg J
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33668625
[TBL] [Abstract][Full Text] [Related]
2. Development of an Anti-canine PD-L1 Antibody and Caninized PD-L1 Mouse Model as Translational Research Tools for the Study of Immunotherapy in Humans.
Oh W; Kim AMJ; Dhawan D; Kirkham PM; Ostafe R; Franco J; Aryal UK; Carnahan RH; Patsekin V; Robinson JP; Knapp DW; Lim SO
Cancer Res Commun; 2023 May; 3(5):860-873. PubMed ID: 37377896
[TBL] [Abstract][Full Text] [Related]
3. A Novel PD-L1 Antibody Promotes Antitumor Function of Peripheral Cytotoxic Lymphocytes after Radical Nephrectomy in Patients with Renal Cell Carcinoma.
An Z; Hsu MA; Gicobi JK; Xu T; Harrington SM; Zhang H; Pavelko KD; Hirdler JB; Lohse CM; Nabavizadeh R; Pessoa RR; Sharma V; Thompson RH; Leibovich BC; Dong H; Lucien F
J Immunol; 2023 Jun; 210(12):2029-2037. PubMed ID: 37163328
[TBL] [Abstract][Full Text] [Related]
4. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
Mahoney KM; Freeman GJ; McDermott DF
Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
[TBL] [Abstract][Full Text] [Related]
5. Current status and perspectives in translational biomarker research for PD-1/PD-L1 immune checkpoint blockade therapy.
Ma W; Gilligan BM; Yuan J; Li T
J Hematol Oncol; 2016 May; 9(1):47. PubMed ID: 27234522
[TBL] [Abstract][Full Text] [Related]
6. PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy
Wang Y; Rousset X; Prunier C; Garcia P; Dosda E; Leplus E; Viallet J
Cancers (Basel); 2022 Jun; 14(13):. PubMed ID: 35804865
[TBL] [Abstract][Full Text] [Related]
7. Comprehensive immunophenotyping of solid tumor-infiltrating immune cells reveals the expression characteristics of LAG-3 and its ligands.
Garman B; Jiang C; Daouti S; Kumar S; Mehta P; Jacques MK; Menard L; Manjarrez-Orduno N; Dolfi S; Mukherjee P; Rai SC; Lako A; Koenitzer JD; David JM
Front Immunol; 2023; 14():1151748. PubMed ID: 37795090
[TBL] [Abstract][Full Text] [Related]
8. Deep Sequencing of T-Cell Receptors for Monitoring Peripheral CD8
Sheng J; Wang H; Liu X; Deng Y; Yu Y; Xu P; Shou J; Pan H; Li H; Zhou X; Han W; Sun T; Pan H; Fang Y
Front Mol Biosci; 2021; 8():679130. PubMed ID: 34307450
[No Abstract] [Full Text] [Related]
9. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
10. Light on life: immunoscore immune-checkpoint, a predictor of immunotherapy response.
Hijazi A; Antoniotti C; Cremolini C; Galon J
Oncoimmunology; 2023; 12(1):2243169. PubMed ID: 37554310
[TBL] [Abstract][Full Text] [Related]
11. Combinatorial immune checkpoint blockade increases myocardial expression of NLRP-3 and secretion of H-FABP, NT-Pro-BNP, interleukin-1β and interleukin-6: biochemical implications in cardio-immuno-oncology.
Quagliariello V; Passariello M; Bisceglia I; Paccone A; Inno A; Maurea C; Rapuano Lembo R; Manna L; Iovine M; Canale ML; Scherillo M; Ascierto PA; Gabrielli D; De Lorenzo C; Maurea N
Front Cardiovasc Med; 2024; 11():1232269. PubMed ID: 38322766
[TBL] [Abstract][Full Text] [Related]
12. Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence.
Vaddepally RK; Kharel P; Pandey R; Garje R; Chandra AB
Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32245016
[TBL] [Abstract][Full Text] [Related]
13. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
14. Development and pharmacokinetic assessment of a fully canine anti-PD-1 monoclonal antibody for comparative translational research in dogs with spontaneous tumors.
Yoshimoto S; Chester N; Xiong A; Radaelli E; Wang H; Brillantes M; Gulendran G; Glassman P; Siegel DL; Mason NJ
MAbs; 2023; 15(1):2287250. PubMed ID: 38047502
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint molecule expression by B and T cell lymphomas in dogs.
Hartley G; Elmslie R; Dow S; Guth A
Vet Comp Oncol; 2018 Sep; 16(3):352-360. PubMed ID: 29380929
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of lymphocyte-specific programmed cell death protein 1 receptor expression and cytokines in blood and urine in canine urothelial carcinoma patients.
Pinard CJ; Stegelmeier AA; Bridle BW; Mutsaers AJ; Wood RD; Wood GA; Woods JP; Hocker SE
Vet Comp Oncol; 2022 Jun; 20(2):427-436. PubMed ID: 34797014
[TBL] [Abstract][Full Text] [Related]
17. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 mRNA derived from tumor-educated platelets as a potential immunotherapy biomarker in non-small cell lung cancer.
Hu Z; Wang N; Zhang Y; Zhang D; Sun S; Yu H; Lin Y; Zhao X; Wang H; Wu X; Ichiki Y; Watanabe S; Gong Z; Chang J; Wang J
Transl Lung Cancer Res; 2024 Feb; 13(2):345-354. PubMed ID: 38496687
[TBL] [Abstract][Full Text] [Related]
19. Establishment of peripheral blood mononuclear cell-derived humanized lung cancer mouse models for studying efficacy of PD-L1/PD-1 targeted immunotherapy.
Lin S; Huang G; Cheng L; Li Z; Xiao Y; Deng Q; Jiang Y; Li B; Lin S; Wang S; Wu Q; Yao H; Cao S; Li Y; Liu P; Wei W; Pei D; Yao Y; Wen Z; Zhang X; Wu Y; Zhang Z; Cui S; Sun X; Qian X; Li P
MAbs; 2018; 10(8):1301-1311. PubMed ID: 30204048
[TBL] [Abstract][Full Text] [Related]
20. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
